A global leader in proton beam technology

Conventional x-ray radiation is used widely in the treatment of many cancers worldwide. The next generation of particle treatment, using protons, pinpoints tumours more precisely and with more energy thereby offering many patients higher disease-free survival rates.

By minimising damage to surrounding healthy tissue, side effects are reduced and by using more concentrated energy, tumour cells are destroyed more effectively.

Share
Price
3.60 p

London Stock Exchange price updated every 20 minutes.

 
Investors

Investors

As a specialist developer of innovative medical devices, AVO's focus is to deliver market changing technology to offer a 1, 2 or 3 room turnkey system for significantly less capital outlay and lower running costs.

Read more
About AVO

About AVO

We are leaders in the next generation of proton systems which do not require a cyclotron or synchrotron. AVO develops cost effective treatments which are clinically superior to those currently available.

Read more

Investor news